The Financial Times' article "Fears over a medical gold rush in cancer drug race" highlighted an unintended theme - the increasing difficulty of finding participants for the almost 800 trials under way. CROs are becomingly increasingly important in this area due to their ability to recruit and screen suitable candidates to complete trials successfully. Big pushes into new drug areas like this can only be good news for businesses like Quotient Clinical, which featured in the Catalyst Pharma Fast 50 published earlier this year.